Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:IKNANASDAQ:IVVDNYSE:JATT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.05+7.1%$1.10$0.86▼$3.92$63.60M0.09290,956 shs168,860 shsIKNAIkena Oncology$1.14+0.9%$1.23$0.97▼$1.94$55.01M0.47168,938 shs37,274 shsIVVDInvivyd$0.84+29.7%$0.65$0.35▼$2.74$100.50M0.44.38 million shs5.43 million shsJATTJATT Acquisition$1.21-4.0%$1.28$7.80▼$12.38$20.87MN/A41,322 shs124,568 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%-9.25%-11.70%-29.49%-70.83%IKNAIkena Oncology0.00%-9.20%+3.18%-21.72%-12.02%IVVDInvivyd0.00%+1.69%+16.39%-59.30%-71.73%JATTJATT Acquisition0.00%-17.69%-0.82%-27.11%-74.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.3647 of 5 stars3.72.00.00.02.51.70.6IKNAIkena Oncology2.8186 of 5 stars3.33.00.00.03.01.71.3IVVDInvivyd3.5728 of 5 stars3.64.00.00.02.13.31.3JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33598.41% UpsideIKNAIkena Oncology 2.50Moderate Buy$3.00163.16% UpsideIVVDInvivyd 3.25Buy$7.52797.19% UpsideJATTJATT Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ABOS, IVVD, JATT, and IKNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.003/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/20/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/5/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.002/24/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/24/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AIKNAIkena Oncology$659K83.48N/AN/A$3.52 per share0.32IVVDInvivyd$25.38M3.96N/AN/A$1.61 per share0.52JATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.71N/AN/AN/AN/A-32.99%-27.99%5/13/2025 (Estimated)IKNAIkena Oncology-$68.17M-$0.86N/AN/AN/AN/A-36.88%-33.08%5/12/2025 (Estimated)IVVDInvivyd-$198.64M-$1.44N/A7.62N/AN/A-155.33%-114.88%N/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ALatest ABOS, IVVD, JATT, and IKNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.94N/AN/AN/AN/AN/A5/12/2025Q1 2025IKNAIkena Oncology-$0.21-$0.18+$0.03-$0.18N/AN/A3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/A3/20/2025Q4 2024IVVDInvivyd-$0.25-$0.15+$0.10-$0.15$13.57 million$13.80 million3/11/2025Q4 2024IKNAIkena Oncology-$0.23-$0.18+$0.05-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43IKNAIkena OncologyN/A15.3215.32IVVDInvivydN/A1.921.58JATTJATT AcquisitionN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%IKNAIkena Oncology75.00%IVVDInvivyd70.36%JATTJATT Acquisition47.97%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%IKNAIkena Oncology5.94%IVVDInvivyd25.40%JATTJATT Acquisition20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableIKNAIkena Oncology7048.26 million45.39 millionNot OptionableIVVDInvivyd100119.96 million98.21 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableABOS, IVVD, JATT, and IKNA HeadlinesRecent News About These CompaniesCautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive RisksDecember 25, 2024 | markets.businessinsider.comZura Bio (ZURA) Receives a Buy from Piper SandlerDecember 13, 2024 | markets.businessinsider.comCautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial UncertaintyNovember 11, 2024 | markets.businessinsider.comThe Legend of Maula Jatt Review: Fawad Khan’s GoT-Coded War Epic Is Derivative, RIdden With ClichesOctober 4, 2024 | moneycontrol.comRelease of Fawad Khan’s Pakistani blockbuster ‘The Legend of Maula Jatt’ halted in IndiaOctober 4, 2024 | thehindu.comPakistani hit The Legend of Maula Jatt, starring Fawad Khan, Mahira Khan, not to release in India, confirms distributorOctober 4, 2024 | hindustantimes.comIndia puts blockbuster Pakistani film on holdOctober 4, 2024 | bbc.co.uk"What is need to release Pakistani film in India?" Shiv Sena (UBT) opposes release of 'The Legend of Maula Jatt'September 22, 2024 | malaysiasun.comShiv Sena (UBT) leader Anand Dubey opposes release of Pakistani film 'The Legend of Maula Jatt' in IndiaSeptember 22, 2024 | malaysiasun.com‘Jatt & Juliet 3’ OTT release: When and where to watch the Diljit Dosanjh and Neeru Bajwa starrer rom-comAugust 27, 2024 | timesofindia.indiatimes.comBahdarpur Jatt Pin CodeApril 10, 2024 | indiatvnews.comNishikant Dubey, wife booked in med college acquisition caseMarch 31, 2024 | timesofindia.indiatimes.comSen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. SteelDecember 22, 2023 | pennlive.comMicrosoft poised to close massive Activision Blizzard acquisition next weekOctober 9, 2023 | vg247.comThe Legend of Maula Jatt to be released in cinemas on ThursdayJuly 8, 2023 | radio.gov.pkPakistani film The Legend of Maula Jatt reunites South Asian communities in Antwerp BelgiumJune 15, 2023 | radio.gov.pkZura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% UpsideMay 24, 2023 | msn.comI Am A Jaat. People Often Confuse Me For A Jatt. Here’s The Difference Between The TwoApril 28, 2023 | scoopwhoop.comZura Bio Announces Appointment of Chief Scientific OfficerApril 16, 2023 | businesswire.comTalkTalk, the Issa brothers and AO: The 19 latest deals from across the North WestMarch 30, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABOS, IVVD, JATT, and IKNA Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.05 +0.07 (+7.13%) Closing price 04:00 PM EasternExtended Trading$1.05 0.00 (0.00%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Ikena Oncology NASDAQ:IKNA$1.13 +0.00 (+0.09%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Invivyd NASDAQ:IVVD$0.84 +0.19 (+29.67%) Closing price 04:00 PM EasternExtended Trading$0.85 +0.01 (+1.34%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.JATT Acquisition NYSE:JATT$1.21 -0.05 (-3.97%) As of 05/9/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
